The Patent Finder

Terms ending in 2041

Sandoz AG

Every in-force patent on Sandoz AG's record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,970,450Multi-Component Crystals of an Orally Available Hif Prolyl Hydroxylase Inhibitor
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 11,273,128Elagolix Formulation
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 12,043,590Co-Crystals Comprising Levothyroxine And A Dicarboxylic Acid
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 12,605,506Automatic Drug Delivery Device
In force
 · High confidence
Novartis AGIn forceHigh confidence
US 12,161,843Automatic Drug Delivery Device
In force
 · High confidence
Novartis AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Sandoz AG.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited